Level A· Stronger Clinical EvidenceSystematic Review

Adipose-derived Mesenchymal Stem Cells in the Treatment of Obesity: A Systematic Review of Longitudinal Studies on Preclinical Evidence.

Saleh F., Itani L., Calugi S., Dalle Grave R., El Ghoch M.

Systematic Review on Type 2 Diabetes, published in Curr Stem Cell Res Ther (2018) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type: Systematic Review
Journal: Curr Stem Cell Res Ther (2018)
Country: United Arab Emirates
Reported sample size: —
PMID: 29766824
DOI: 10.2174/1574888X13666180515160008

Abstract (original English)

Obesity is an increasing global health problem, but its treatment is not yet optimal, especially in the long term. For this reason, preclinical studies have been conducted relating to a new therapeutic strategy for obesity based on adipose-derived mesenchymal stem cells (AD-MSCs). The aim of our systematic review is to summarize these findings deriving from the animal model in order to establish whether there is sufficient evidence to justify going forward to clinical studies. Literature searches, study selection, methods and quality appraisal were performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data were collated using a narrative approach. Of the 578 articles retrieved, seven studies met the inclusion criteria, and their analysis revealed several main findings. There was a strong evidence of the positive effect of AD-MSCs in obesity treatment in terms of body weight, glucose metabolism homeostasis, lipid profiles, non-alcoholic fatty liver disease and systemic inflammation. Moreover, there was recent evidence from a few studies for a significant effect of AD-MSCs transplantation on the improvement of obesity-related hormonal status, (i.e., leptin) and body composition patterns, though these investigations may need further replication. The effects of AD-MSCs transplantation on obesity, in terms of weight loss and obe

What this study does not prove

• This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Adipose TissueAnimalsDisease Models, AnimalHumansLongitudinal StudiesMesenchymal Stem Cell TransplantationMesenchymal Stem CellsObesity

Systemic / IV Type 2 Diabetes

View on PubMed DOI

Adipose-derived Mesenchymal Stem Cells in the Treatment of Obesity: A Systematic Review of Longitudinal Studies on Preclinical Evidence.

Abstract (original English)

What this study does not prove

Evidence level

Related research

Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.

Type 2 Diabetes Mellitus Induced Paracrine Effects on Breast Cancer Metastasis Through Extracellular Vesicles Derived from Human Mesenchymal Stem Cells.

Metabolic effects of large-volume liposuction for obese healthy women: a meta-analysis of fasting insulin levels.

Safety and efficacy of autologous adipose tissue-derived stem cell transplantation in aging-related low-grade inflammation patients: a single-group, open-label, phase I clinical trial.

Using adipose-derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand?

The possible role of visceral fat in early pregnancy as a predictor of gestational diabetes mellitus by regulating adipose-derived exosomes miRNA-148 family: protocol for a nested case-control study in a cohort study.